SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results